FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285388047> ?p ?o ?g. }

• W4285388047 abstract "Background This is an updated version of the Cochrane Review published in 2015. Epilepsy is a chronic neurological disorder, characterised by recurring, unprovoked seizures. Vagus nerve stimulation (VNS) is a neuromodulatory treatment that is used as an adjunctive therapy for treating people with drug‐resistant epilepsy. VNS consists of chronic, intermittent electrical stimulation of the vagus nerve, delivered by a programmable pulse generator. Objectives To evaluate the efficacy and tolerability of VNS when used as add‐on treatment for people with drug‐resistant focal epilepsy. Search methods For this update, we searched the Cochrane Register of Studies (CRS), and MEDLINE Ovid on 3 March 2022. We imposed no language restrictions. CRS Web includes randomised or quasi‐randomised controlled trials from the Specialised Registers of Cochrane Review Groups, including Epilepsy, CENTRAL, PubMed, Embase, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform. Selection criteria We considered parallel or cross‐over, randomised, double‐blind, controlled trials of VNS as add‐on treatment, which compared high‐ and low‐level stimulation (including three different stimulation paradigms: rapid, mild, and slow duty‐cycle), and VNS stimulation versus no stimulation, or a different intervention. We considered adults or children with drug‐resistant focal seizures who were either not eligible for surgery, or who had failed surgery. Data collection and analysis We followed standard Cochrane methods, assessing the following outcomes: 1. 50% or greater reduction in seizure frequency2. Treatment withdrawal (any reason)3. Adverse effects4. Quality of life (QoL)5. Cognition6. Mood Main results We did not identify any new studies for this update, therefore, the conclusions are unchanged. We included the five randomised controlled trials (RCT) from the last update, with a total of 439 participants. The baseline phase ranged from 4 to 12 weeks, and double‐blind treatment phases from 12 to 20 weeks. We rated two studies at an overall low risk of bias, and three at an overall unclear risk of bias, due to lack of reported information about study design. Effective blinding of studies of VNS is difficult, due to the frequency of stimulation‐related side effects, such as voice alteration. The risk ratio (RR) for 50% or greater reduction in seizure frequency was 1.73 (95% confidence interval (CI) 1.13 to 2.64; 4 RCTs, 373 participants; moderate‐certainty evidence), showing that high frequency VNS was over one and a half times more effective than low frequency VNS. The RR for treatment withdrawal was 2.56 (95% CI 0.51 to 12.71; 4 RCTs, 375 participants; low‐certainty evidence). Results for the top five reported adverse events were: hoarseness RR 2.17 (99% CI 1.49 to 3.17; 3 RCTs, 330 participants; moderate‐certainty evidence); cough RR 1.09 (99% CI 0.74 to 1.62; 3 RCTs, 334 participants; moderate‐certainty evidence); dyspnoea RR 2.45 (99% CI 1.07 to 5.60; 3 RCTs, 312 participants; low‐certainty evidence); pain RR 1.01 (99% CI 0.60 to 1.68; 2 RCTs; 312 participants; moderate‐certainty evidence); paraesthesia 0.78 (99% CI 0.39 to 1.53; 2 RCTs, 312 participants; moderate‐certainty evidence). Results from two studies (312 participants) showed that a small number of favourable QOL effects were associated with VNS stimulation, but results were inconclusive between high‐ and low‐level stimulation groups. One study (198 participants) found inconclusive results between high‐ and low‐level stimulation for cognition on all measures used. One study (114 participants) found the majority of participants showed an improvement in mood on the Montgomery–Åsberg Depression Rating Scale compared to baseline, but results between high‐ and low‐level stimulation were inconclusive. We found no important heterogeneity between studies for any of the outcomes. Authors' conclusions VNS for focal seizures appears to be an effective and well‐tolerated treatment. Results of the overall efficacy analysis show that high‐level stimulation reduced the frequency of seizures better than low‐level stimulation. There were very few withdrawals, which suggests that VNS is well tolerated. Adverse effects associated with implantation and stimulation were primarily hoarseness, cough, dyspnoea, pain, paraesthesia, nausea, and headache, with hoarseness and dyspnoea more likely to occur with high‐level stimulation than low‐level stimulation. However, the evidence for these outcomes is limited, and of moderate to low certainty. Further high‐quality research is needed to fully evaluate the efficacy and tolerability of VNS for drug‐resistant focal seizures." @default.
• W4285388047 created "2022-07-14" @default.
• W4285388047 creator A5013963114 @default.
• W4285388047 creator A5078322794 @default.
• W4285388047 creator A5083268902 @default.
• W4285388047 date "2022-07-14" @default.
• W4285388047 modified "2023-10-17" @default.
• W4285388047 title "Vagus nerve stimulation for focal seizures" @default.
• W4285388047 cites W129888043 @default.
• W4285388047 cites W1509856631 @default.
• W4285388047 cites W1533692490 @default.
• W4285388047 cites W1591860610 @default.
• W4285388047 cites W1605548529 @default.
• W4285388047 cites W1847659220 @default.
• W4285388047 cites W1874374303 @default.
• W4285388047 cites W1896131912 @default.
• W4285388047 cites W1907168917 @default.
• W4285388047 cites W1963495731 @default.
• W4285388047 cites W1965258124 @default.
• W4285388047 cites W1967331310 @default.
• W4285388047 cites W1969986880 @default.
• W4285388047 cites W1970270672 @default.
• W4285388047 cites W1974809694 @default.
• W4285388047 cites W1989083357 @default.
• W4285388047 cites W1993528581 @default.
• W4285388047 cites W1993874893 @default.
• W4285388047 cites W1995764960 @default.
• W4285388047 cites W2001944673 @default.
• W4285388047 cites W2006689666 @default.
• W4285388047 cites W2008984641 @default.
• W4285388047 cites W2012201023 @default.
• W4285388047 cites W2012640962 @default.
• W4285388047 cites W2018368033 @default.
• W4285388047 cites W2022305238 @default.
• W4285388047 cites W2024297318 @default.
• W4285388047 cites W2027557983 @default.
• W4285388047 cites W2042749550 @default.
• W4285388047 cites W2046391772 @default.
• W4285388047 cites W2054567737 @default.
• W4285388047 cites W2061147578 @default.
• W4285388047 cites W2068060099 @default.
• W4285388047 cites W2068101716 @default.
• W4285388047 cites W2076133645 @default.
• W4285388047 cites W2076993158 @default.
• W4285388047 cites W2078834347 @default.
• W4285388047 cites W2081393436 @default.
• W4285388047 cites W2083515975 @default.
• W4285388047 cites W2092064447 @default.
• W4285388047 cites W2096042849 @default.
• W4285388047 cites W2096688703 @default.
• W4285388047 cites W2098647834 @default.
• W4285388047 cites W2109055597 @default.
• W4285388047 cites W2121065508 @default.
• W4285388047 cites W2124330224 @default.
• W4285388047 cites W2126642067 @default.
• W4285388047 cites W2128174510 @default.
• W4285388047 cites W2157595383 @default.
• W4285388047 cites W2171565404 @default.
• W4285388047 cites W2174408996 @default.
• W4285388047 cites W2192396192 @default.
• W4285388047 cites W2201348756 @default.
• W4285388047 cites W2280141967 @default.
• W4285388047 cites W2281839376 @default.
• W4285388047 cites W2289451589 @default.
• W4285388047 cites W2322607235 @default.
• W4285388047 cites W2442539006 @default.
• W4285388047 cites W2555106703 @default.
• W4285388047 cites W2592509339 @default.
• W4285388047 cites W2605041831 @default.
• W4285388047 cites W2607074866 @default.
• W4285388047 cites W2607586607 @default.
• W4285388047 cites W2793573970 @default.
• W4285388047 cites W2904718252 @default.
• W4285388047 cites W2911932764 @default.
• W4285388047 cites W2945648942 @default.
• W4285388047 cites W2947977273 @default.
• W4285388047 cites W2973452758 @default.
• W4285388047 cites W2974858420 @default.
• W4285388047 cites W2998733648 @default.
• W4285388047 cites W3139076223 @default.
• W4285388047 cites W3151064539 @default.
• W4285388047 cites W4244884447 @default.
• W4285388047 cites W4292167789 @default.
• W4285388047 doi "https://doi.org/10.1002/14651858.cd002896.pub3" @default.
• W4285388047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35833911" @default.
• W4285388047 hasPublicationYear "2022" @default.
• W4285388047 type Work @default.
• W4285388047 citedByCount "6" @default.
• W4285388047 countsByYear W42853880472015 @default.
• W4285388047 countsByYear W42853880472022 @default.
• W4285388047 countsByYear W42853880472023 @default.
• W4285388047 crossrefType "journal-article" @default.
• W4285388047 hasAuthorship W4285388047A5013963114 @default.
• W4285388047 hasAuthorship W4285388047A5078322794 @default.
• W4285388047 hasAuthorship W4285388047A5083268902 @default.
• W4285388047 hasBestOaLocation W42853880472 @default.
• W4285388047 hasConcept C118552586 @default.
• W4285388047 hasConcept C126322002 @default.
• W4285388047 hasConcept C142724271 @default.
• W4285388047 hasConcept C168563851 @default.

• next